We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

47 hedge funds and large institutions have $3.37M invested in Matinas BioPharma in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0.24% → 0.24% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

8% less funds holding

Funds holding: 51 → 47 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

64% less capital invested

Capital invested by funds: $9.31M → $3.37M (-$5.93M)

Holders
47
Holders Change
-4
Holders Change %
-7.84%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$185K
2
Squarepoint
Squarepoint
New York
+$36.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$16.8K
4
PAG
Private Advisor Group
New Jersey
+$10.3K
5
TRCT
Tower Research Capital (TRC)
New York
+$9.51K

Top Sellers

Rank Fund Capital Flow
1
CCM
Courage Capital Management
Tennessee
-$119K
2
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
-$49.1K
3
VF
Virtu Financial
New York
-$33K
4
Charles Schwab
Charles Schwab
California
-$28.2K
5
BCM
Bridgeway Capital Management
Texas
-$24.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$6K – – –
JP Morgan Chase
27
JP Morgan Chase
New York
$5.88K +$61 +5 +0.6%
NWMG
28
National Wealth Management Group
Ohio
$5.56K -$246 -20 -2%
Jane Street
29
Jane Street
New York
$4.49K +$8.47K +690 New
XT
30
XTX Topco
Cayman Islands
$4.41K +$8.33K +678 New
Morgan Stanley
31
Morgan Stanley
New York
$3.9K – – –
BBA
32
Baader Bank Aktiengesellschaft
Germany
$3.77K +$5.16K +420 +167%
DAS
33
Dynamic Advisor Solutions
Arizona
$3.59K – – –
RPC
34
Rossmore Private Capital
Connecticut
$2.27K – – –
CFG
35
Cooper Financial Group
California
$1.81K – – –
Osaic Holdings
36
Osaic Holdings
Arizona
$1.56K -$246 -20 -8%
CG
37
Clarus Group
Texas
$1.56K – – –
JWCA
38
J.W. Cole Advisors
Florida
$1.4K – – –
CFS
39
CRA Financial Services
New Jersey
$1.3K – – –
MFG
40
Magnus Financial Group
New York
$1.3K – – –
SW
41
SlateStone Wealth
Florida
$1K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$1K +$86 +7 +5%
SPIA
43
Steward Partners Investment Advisory
New York
$395 – – –
EWA
44
EverSource Wealth Advisors
Alabama
$390 – – –
HFM
45
Hartford Financial Management
Connecticut
$325 – – –
GWMIA
46
Global Wealth Management Investment Advisory
Florida
$85 – – –
IA
47
IFP Advisors
Florida
$83 – – –
CCM
48
Courage Capital Management
Tennessee
– -$119K -6,637 Closed
VF
49
Virtu Financial
New York
– -$33K -1,806 Closed
Charles Schwab
50
Charles Schwab
California
– -$28.2K -1,568 Closed
1
2
3

MTNB Hedge Fund Activity: Q3 2023 in Review

47 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2023, worth a combined $3.37M — down 64% from $9.31M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MTNB and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $185K. The largest seller was Courage Capital Management, exiting entirely with an estimated $119K sold.

  • 47 institutional investors held Matinas BioPharma (MTNB) as of Q3 2023, down from 51 in Q2 2023.
  • Funds reported $3.37M of Matinas BioPharma stock for Q3 2023, down 64% quarter-over-quarter.
  • 4 funds opened new Matinas BioPharma positions in Q3 2023 and 8 closed out, a net change of -4 holders.
  • The largest Matinas BioPharma buyer in Q3 2023 was Jacobs Levy Equity Management, an estimated $185K added.
  • The largest Matinas BioPharma seller in Q3 2023 was Courage Capital Management, an estimated $119K sold.

Based on aggregated 13F filings for Q3 2023.